Withdrawal notice to: "Pan-cancer analyses of clinical prognosis, immune infiltration, and immunotherapy efficacy for TRPV family using multi-omics data" [Heliyon 9, (2023) 16897]

Chong Shen; Chong Fu; Yong Suo; Kai Li; Zhe Zhang; Shaobo Yang; Yu Zhang; Yuda Lin; Zhi Li; Zhouliang Wu; Shiwang Huang; Houyuan Chen; Zhenqian Fan; Hailong Hu

doi:10.1016/j.heliyon.2023.e17229

Withdrawal notice to: "Pan-cancer analyses of clinical prognosis, immune infiltration, and immunotherapy efficacy for TRPV family using multi-omics data" [Heliyon 9, (2023) 16897]

Heliyon. 2023 Jun 14;9(6):e17229. doi: 10.1016/j.heliyon.2023.e17229. eCollection 2023 Jun.

Authors

Chong Shen^{1

2}, Chong Fu^{1

2}, Yong Suo^{1

2}, Kai Li^{1

2}, Zhe Zhang^{1

2}, Shaobo Yang^{1

2}, Yu Zhang^{1

2}, Yuda Lin^{1

2}, Zhi Li^{1

2}, Zhouliang Wu^{1

2}, Shiwang Huang^{1

2}, Houyuan Chen^{1

2}, Zhenqian Fan³, Hailong Hu^{1

2}

Affiliations

¹ Department of Urology, Tianjin Institute of Urology, The Second Hospital of Tianjin Medical University, Tianjin, 300211, China.
² Tianjin Key Laboratory of Urology, Tianjin Institute of Urology, The Second Hospital of Tianjin Medical University, Tianjin, China.
³ Department of Endocrinology, The Second Hospital of Tianjin Medical University, Tianjin, China.

Abstract

[This corrects the article DOI: 10.1016/j.heliyon.2023.e16897.].

Publication types

Retraction of Publication